---
schema_version: "secwatch.filing_event.v1"
accession: "0001503274-25-000004"
form_type: "8-K"
ticker: "QTRX"
cik: "0001503274"
company_name: "Quanterix Corp"
filed_at: "2025-01-10T23:59:59+00:00"
generated_at: "2026-05-28T04:52:52.392102+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Quanterix to acquire Akoya Biosciences; expands addressable market to $5B

## Summary
- Transaction expected to close in Q2 2025; combined cash at close ~$175M.
- Combined installed base of 2,300+ instruments; addressable market grows from $1B to $5B.
- Expands Quanterix from neurology into oncology and immunology via Akoya's tissue biomarker platform.
- Post-closing, combined company will operate under Quanterix name; integration team being formed.

## SEC filing metadata
- accession: 0001503274-25-000004
- form_type: 8-K
- ticker: QTRX
- cik: 0001503274
- company_name: Quanterix Corp
- filed_at: 2025-01-10T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1503274/000150327425000004/0001503274-25-000004-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1503274/000150327425000004/qtrx-20250110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001503274-25-000004
- JSON: https://secwatch.observer/filing/0001503274-25-000004.json
- Plain text: https://secwatch.observer/filing/0001503274-25-000004.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.